HOME >> BIOLOGY >> NEWS
Other highlights in the August 4 JNCI

ut its association with response to taxane-based chemotherapy is not clear. Dennis J. Slamon, M.D., Ph.D., of the University of California, Los Angeles, and colleagues analyzed retrospective data from a randomized clinical trial that had treated patients with metastatic breast cancer with either taxane-based epirubicinpaclitaxel (ET) chemotherapy or epirubicincyclophosphamide (EC) chemotherapy.

They found that HER-2/neu overexpression does not adversely influence response to first-line ET or EC chemotherapy and that a taxane-containing regimen, such as ET, may provide a preferential benefit to patients with tumors that overexpress HER-2/neu.

Contact: Kim Irwin, Women's Cancer Program Area, Jonsson Cancer Center, 310-206-2805, kirwin@mednet.ucla.edu

Researchers Examine Targeted Therapy for Neuroblastoma in Mouse Model

Survival is poor in patients with advanced-stage neuroblastoma, a cancer of nerve cells in infants and children, and there is a need to develop better treatments. Mirco Ponzoni, Ph.D., of G. Gaslini Children's Hospital in Genoa, Italy, and colleagues show that by encapsulating an antisense oligonucleotide targeting an oncogene and activating the innate immune system in a liposome that specifically targets neuroblastoma cells, neuroblastoma-bearing mice lived longer than mice given any other treatment in the study.

Contact: Mirco Ponzoni, G. Gaslini Children's Hospital, 39-010-563-6342, mircoponzoni@ospedale-gaslini.ge.it

Also in the August 4 JNCI:

  • No Survival Benefit for Adjuvant Chemotherapy for Colon Cancer after 10 Years:
    http://www.eurekalert.org/emb_releases/2004-08/jotn-acf072904.php
  • Activated Signaling Pathway May Predict Lung Cancer Patients' Response to Gefitinib:


  • Contact: Sarah L. Zielinski
    jncimedia@oupjournals.org
    301-841-1287
    Journal of the National Cancer Institute
    3-Aug-2004


    Page: 1 2 3

    Related biology news :

    1. Other highlights in the September 1 JNCI
    2. Other highlights in the August 18 JNCI
    3. Other highlights in the July 7 JNCI
    4. Other highlights in the June 16 JNCI
    5. Other Highlights in the June 2 JNCI
    6. Other highlights in the May 19 JNCI
    7. Other highlights in the May 5 JNCI
    8. Other highlights of the March 17 issue of JNCI
    9. Other highlights in the March 3 issue of JNCI
    10. Other highlights in the February 18 issue of JNCI
    11. Other highlights in the February 4 issue of JNCI

    Post Your Comments:
    *Name:
    *Comment:
    *Email:


    (Date:6/9/2016)... innovation leader in attendance control systems is proud to announce the introduction of fingerprint ... sure the right employees are actually signing in, and to even control the opening ... ... ... Photo ...
    (Date:6/2/2016)... YORK , June 2, 2016   The Weather ... is announcing Watson Ads, an industry-first capability in which consumers ... by being able to ask questions via voice or text ... Marketers have long sought ... the consumer, that can be personal, relevant and valuable; and ...
    (Date:5/16/2016)... YORK , May 16, 2016   EyeLock ... solutions, today announced the opening of an IoT Center ... to strengthen and expand the development of embedded iris ... an unprecedented level of convenience and security with unmatched ... authenticate one,s identity aside from DNA. EyeLock,s platform uses ...
    Breaking Biology News(10 mins):
    (Date:6/27/2016)... PHILADELPHIA , June 27, 2016  Liquid ... today announced the funding of a Sponsored Research ... study circulating tumor cells (CTCs) from cancer patients.  ... changes in CTC levels correlate with clinical outcomes ... therapies. These data will then be employed to ...
    (Date:6/24/2016)... , June 24, 2016 Epic Sciences ... detects cancers susceptible to PARP inhibitors by targeting ... cells (CTCs). The new test has already been ... in multiple cancer types. Over 230 ... damage response pathways, including PARP, ATM, ATR, DNA-PK ...
    (Date:6/23/2016)... , ... June 23, 2016 , ... ... release of its second eBook, “Clinical Trials Patient Recruitment and Retention Tips.” Partnering ... retention in this eBook by providing practical tips, tools, and strategies for clinical ...
    (Date:6/23/2016)... 2016 /PRNewswire/ - FACIT has announced the creation ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or "the ... a portfolio of first-in-class WDR5 inhibitors for the ... WDR5 represent an exciting class of therapies, possessing ... for cancer patients. Substantial advances have been achieved ...
    Breaking Biology Technology:
    Cached News: